Loading clinical trials...

Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED) | Clinical Trials | Clareo Health

COMPLETED

Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)

PRAGMATIC (This is the True Official Title of the Protocol for This Study)

NCT00724477•Organon and Co

View on ClinicalTrials.gov

Summary

The main objective of this study is to determine the percentage of patients who met the low-density lipoprotein cholesterol (LDL-C) objective with INEGY, that were not under statin monotherapy treatment.

Detailed Description

The type of patient sampling used was consecutive patient sampling

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•man or woman aged over 18;
•patient suffering from primary hypercholesterolemia;
•patient justifying treatment with INEGY® (2nd intention);
•patient currently treated with INEGY® for at least 4 weeks;
•patient with a lipid profile before treatment with INEGY®, documenting a level of LDL-C exceeding the therapeutic objective under treatment with a statin as monotherapy;
•patient with an evaluation of lipid disorder (EAL) treated with INEGY®, performed within 1 to 3 months of starting treatment.

Exclusion Criteria

•patient not previously treated with a statin;
•patient previously treated with a combination of hypolipemics;
•patient treated with INEGY® as first intention;
•patient treated with INEGY® for less than 4 weeks;
•patient already included in this study.

Key Dates

Start Date

October 1, 2007

Primary Completion Date

August 1, 2008

Completion Date

August 1, 2008

Last Updated

February 9, 2022

Enrollment

1,663

ACTUAL participants

Conditions

Primary Hypercholesterolemia

Interventions

INEGY

DRUG

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

NCT06314919

Primary HypercholesterolemiaMixed Dyslipidemia

View study

RECRUITINGPHASE3

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

NCT06568471

HypercholesterolemiaDyslipidemias+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe